The analysis showed that: (1) KIF23 expression was positively correlated with tumor malignancy (grade, wild-type IDH1, G3, and Mesenchymal subtype preference), (2) patients with higher expression of KIF23 had a shorter survival time than those with lower KIF23 expression, and (3) KIF23 was an independent prognostic biomarker for glioma patients. This evidence concerns the gene KIF23 and neoplasm.